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Summary
Mild hyperhomocystememia is an estabhshed nsk factor for both ar-
tenosclerosis and thrombosis, and may be caused by genetic and envi-
ronmental factors Methylenetetrahydrofolate reductase (MTHFR) cat-
alyzes the reduction of 5,10-rnethylenetetrahydrofolate to 5-methyl-
tetrahydrofolate, the cofactor for the methylation of homocysteme to
methionine Individuais with the thermolabile vanant of MTHFR have
decreased MTHFR activities, resultmg in elevated plasma homocys-
teme concentrations A homozygous 677C-H.T transition m the
MTHFR gene has recently been identified äs the cause of reduced
enzyme activity and thermolability of the protem We studied the fre-
quency of the homozygous mutant (+/+) genotype m 471 patients with
deep-vem thrombosis and 474 healthy controls enrolled m The Leiden
Thrombophilia Study (LETS), its mteraction with factor V Leiden, and
assessed the association between the MTHFR genotypes and plasma
homocysteme concentration Homozygosity for the 677C—>T polymor-
phism was observed in 47 (10%) patients, and m 47 (9 9%) contiols
(OR l 01 [95% CI 07-1 5]) No modified nsk of the (+/+) genotype
was observed m carners of factoi V Leiden Our data suggest that,
although the homozygous mutant genotype is associated with elevated
plasma homocysteme concentrations, this homozygous mutation itself
is not a genetic nsk factor for deep-vem thrombosis, irrespective of fac-
tor V Leiden genotype
Introduction
Mild hyperhomocystememia, a disorder of methionine metabolism,
is an estabhshed nsk factor for artenal cardiovascular disease (1)
Although vascular accidents m homocystmuna due to cystathiomne
ß-synthase deficiency are of venous ongm m 51 % of the cases (2), on-
ly a few studies have explored the relation between mild hyperhomo-
cystememia and venous thrombosis Biattstromeia/ were the first who
exammed a possible relationship between mild hyperhomocystememia
and venous thrombosis m a sex- and age-matched case-control study
(3) They observed mild hyperhomocystememia m 14% of the patients
versus 5% of the controls after methionine loadmg, however, no differ-
ences were found m mean plasma homocysteme concentrations
Amundsen et al (4) did not report a sigmficant difference in mean plas-
ma homocysteme concentrations between young adults (<56 y) with
venous thrombosis and control subjects However, from their data, we
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were able to calculate an odds ratio of l 7 [95% CI 0 5-5 9] for a post-
load homocysteme concentration above 50 μηιοΐ/ΐ (~90th percentile of
their control group) In both studies, no differences were observed,
probably due to the low number of patients and controls mcluded m
both studies Falcon et al (5) found a high prevalence of hyperhomo-
cystememia in patients with juvemle venous thrombosis In their study,
only mean post-methiomne load mcrease m plasma homocysteme m
patients appeared to be different from controls, and post-load hyper-
homocystememia was observed m almost 20% of the cases In subse-
quent studies, Den Heijer et al found similar results on mild hyperhom-
ocystememia m -25% of the patients with recurrent venous thrombosis,
both m fastmg state and after methionine loadmg (6) In the Leiden
Thrombophilia Study (LETS), fastmg homocysteme concentrations
were elevated m patients with deep-vem thrombosis compared with
age- and sex-matched healthy controls, suggestmg that hyperhomocys-
tememia is a nsk factor for deep-vem thrombosis (7)
In 1988, Kang et al (8) descnbed a new vanant of methylenetetra-
hydrofolate reductase (MTHFR) with thermolabile properües and
reduced enzyme activity, resultmg m mildly elevated plasma homocys-
teme concentrations Previously, we have shown that this thermolabile
MTHFR is a cause of abnormal homocysteme metabolism m -28% of
cardiovascular disease patients with mild hyperhomocystememia (9)
We elucidated the genetic basis underlymg this thermolability to be a
677C-^T transition, resultmg m a conserved ammo acid change from
alanine to valme (10) This mutation m homozygous form appeared to
be m high agreement with thermolability of the protem, reduced specif-
ic enzyme activity, and mcreased plasma homocysteme concentrations
(10-12), especially m circumstances of low folate Status (13,14)
In the present study, we mvestigated the 677C—>T mutation äs a nsk
factor for deep-vem thrombosis m 471 patients and m 474 controls
enrolled m the Leiden Thrombophilia Study (LETS), and its mteraction
with factor V Leiden (FVL), the most common hentable cause of deep-
vem thrombosis is studied (15) Furthermore, we assessed the associa-
tion of the mutation to fastmg total plasma homocysteme concentration
m a subset of 269 matched case-control pairs
Patients and Methods
Patients The Leiden Thrombophilia Study (LETS) is a population based
case-control study in three Dutch Anticoagulation Clmics, mcluding 474
patients with a first episode of deep-vem thrombosis and 474 age- and
sex-matched healthy control subjects, designed to clanfy the contnbution of
several nsk factors to deep-vem thrombosis, which has been descnbed m detail
elsewhere(lo)
Methods Genomic DNA was extracted from penpheral blood lymphocytes
by Standard techmques and the MTHFR mutation analysis was performed es
sentially accordmg Frosst et al (10), by a techmcian unaware of the Status of
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the DNA sample. The restriction fragments (198 bp for the 677C allele, and
175 bp and 23 bp for the 677T allele) were separated in 4% agarose gels and
visualized after ethidium bromide staining. Mutation screening for FVL has
been performed earlier (15), in which 92 cases and 14 controls were found to be
carriers of the FVL mutation.
Total plasma homocysteine concentrations were determined in the
269 matched case-control pairs who attended the Leiden Anticoagulation
Chnic (7) by reverse phase HPLC and fluorescent detection, äs described by Te
Poele-Pothoffeia/. (17).
Statistics. Unmatched odds ratios and 95% confidence intervals äs an
estimate of the relative risk of the homozygous (+/+) genotype were calculated
m the entire study population, in the Leiden subgroup, and in different age and
sex groups. The 95% Confidence Intervals were calculated from a conditional
logistic-regression algorithm by the maximum likelihood method, with Egret
Software. To assess the relation between the mutation and homocysteine level,
we calculated homocysteine concentrations in different genotype groups, and
prevalences of the three genotypes in different strata of homocysteine levels.
The possible effect modification by FVL genotype, i.e. whether the MTHFR
variant exerted a different effect in FVL carriers than in non-carriers, was ex-
amined by stratified analysis. We subdivided cases and controls in those with
neither, one, or both of the variant genotypes, and calculated unmatched odds
ratios äs estimates of the relative risk of thrombosis for each group relative to
those with double wildtype genotype.
Results
The mean age for the entire study group was 44 years (ränge 16-70
in patients, and 16-71 in controls). The male to female ratio was 1:1.3
for cases and controls alike (7).
Fasting plasma homocysteine concentrations were determined in
269 out of 474 matched case-control pairs. Mediän plasma homocys-
teine concentration was elevated in cases compared to controls
(12.9 μηιοΐ/ΐ; ränge 4.8-60.2 μηιοΐ/ΐ, versus 12.3 μηιοΐ/ΐ; ränge
6.4-37.5 μηιοΐ/ΐ, respectively) (7). Mild hyperhomocysteinemia, de-
fined äs a fasting total plasma homocysteine concentration >18.5
μηιοΐ/ΐ (i.e. above the 95th percentile of the control group), resulted in
a matched odds ratio of 2.5 (95% Confidence Interval: 1.2-5.2) (7).
The prevalence of the 677C->T transition was examined in 471 pa-
tients with deep-vein thrombosis and in 474 healthy controls. We
observed a prevalence of the homozygous mutant genotype (+/+) in
47 (10%) out of 471 patients, versus 47 (9.9%) out of 474 healthy con-
trols (Table 1). The unmatched odds ratio, äs an estimate of relative risk
of deep-vein thrombosis, for homozygous mutant (+/+) individuals
relative to heterozygous (+/-) and homozygous normal (-/-) individuals
was 1.01 (95% Confidence Interval: 0.7-1.5).
The prevalence of the homozygous mutant genotype (+/+) in a sub-
set of 269 matched case-control pairs for whom plasma homocysteine
measurements were performed, was 10.4% (28 out of 269) in cases, and
8.6% (23 out of 269) in controls, which is not substantially different
from the overall result. In this subgroup, we associated the MTHFR
genotype to homocysteine concentrations in plasma. As shown in
Table 2, homocysteine concentrations were higher among individuals
with the homoz,ygous mutant genotype (+/+) compared with heterozy-
gous (+/-) and (-/-) individuals. We then subdivided this population in
different homocysteine strata and calculated the MTHFR genotype
distribution, Fig. 1. In the lowest three homocysteine strata, the fre-
quency of the (+/+) genotype was <10%, whereas in the higher strata
the frequency increased from 12-15% to more than 50% in the highest
stratum. These results indicate that this mutation is a significant
contributor to elevated homocysteine concentrations.
In 11 out of 28 (+/+) cases (39%), mild hyperhomocysteinemia was
observed compared with 4 out of 23 (+/+) controls (17.4%). The latter
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Plasma homocysteine concentrations are expressed in μιηοΙ/L äs mean ± SD.
indicates that (+/+) cases are more prone to develop a mild hyper-
homocysteinemia than controls from the same genotype group. In men
we found an odds ratio for the (+/+) genotype slightly below one, and
for women slightly above one; both these estimates had wide confi-
dence limits (men: OR 0.76 [95% Confidence Interval: 0.40-1.44];
women: OR 1.33 [95% Confidence Interval: 0.69-2.61]. No differ-
ences were observed in different age groups (Table 3).
We also studied the interaction of thermolabile MTHFR with the
most common inherited cause of deep-vein thrombosis: APC resistance
due to FVL. In these analyses, we calculated unmatched odds ratios for
deep-vein thrombosis due to either MTHFR, FVL or both risk geno-
types, relative to those individuals with neither of these risk genotypes





Fig. l MTHFR genotype distribution in different homocysteine strata.
Homocysteine concentrations are expressed in μηιοΐ/ΐ. In each homocysteine
stratum, the number of individuals is set to 100%
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relatwely small, we observed no modified nsk of the MTHFR (+/+)
genotype by concomitant FVL Foi a summaiy estimate of the iclative
nsk of venous thrombosis m jomtly affected individuals, we combmed
three studies recently piesented at the XVIth Congiess of the Intel na-
tional Society on Thrombosis and Haemostasis, Floience, Italy, in
which we were able to calculate the genotype distnbutions of both
mutations m cases and controls (18 20), and combmed them with the
present study Overall, the homozygous mutant (+/+) genotype in the
MTHFR gene was obseived m 1 17 (14 4%) out of 810 cases, and m
121(13 9%) out of 870 controls (OR l 0 [95% CI 0 8 l 4]) FVL was
detected m 164 (202%) cases and m 26 (30%) contiols (OR 82
[95% CI 54-126 ]), whereas the coexistence of both mutations
was observed m 26 (3 2%) cases and m 4 (0 5%) controls (OR 7 2
[95% CI 25-207]) These summary estimates mdicate that the
MTHFR 677C->T vanant itself is not a nsk factoi for venous thrombo
sis, and does not modify the nsk m individuals with FVL genotype
Discussion
Homozygosity foi the 677C^T mutation in the MTHFR gene is äs
sociated with elevated plasma homocysteme concentrations However,
this homozygous mutation is not associated with an mcieased nsk of
deep-vem thrombosis, wheieas mild hyperhomocystememia is (7)
Den Heijer et al (7) found a 2 5-fold mcreased nsk [95% CI
l 7-3 7] for a homocysteme concentration above 18 5 mmol/L (95 th
peicentile of the control group) in the geneial population This result
and those from othei studies (3, 5, 6) all suggested that mild hypei
homocystemerma is a nsk factor for occurrence and recurrence of ve-
nous thrombosis, which resembles the association obseived in aitenal
cardiovascular disease (21)
Elevated plasma homocysteme concentrations may ongmate fiom
nutntional deficiencies (low folate, Vitamin B-12 or vitamm B-6 Status)
or fiom genetic aberrations in enzymes mvolved in homocysteme me-
tabolism The lecently detected homozygous 677C^T transition m the
MTHFR gene has been shown to be associated with elevated mean
plasma homocysteme concentrations (10, 11) By combming eight
case-control studies m a meta analysis, we weie able to show that this
mutation is a lather modest but sigmficant nsk factor confeinng a 22%
higher nsk foi coronary aiteiy disease (22) In the present study, mild
hyperhomocystememia, defmed äs a homocysteme concentiation
exceeding the 95th peicentile of the control group (>18 5 μιτιοΐ/ΐ), was
observed m 28 (10%) out of 269 patients We observed that the homo-
zygous mutation is a contnbutoi to elevated plasma homocysteme con
tentiations, which is m agieement with several othei studies (10-12)
However, we found no difterence m prevalence of the 677C-^T transi-
tion m patients with a first episode of venous thrombosis, mdicatmg
that disturbed homocysteme lemethylation due to this genetic defect
alone seems not a nsk factoi for deep vem thrombosis
Several explanations may be offeied
(l ) Recent studies by lacques et al (13) and Van der Put et al (14),
demonstrated a stiong mteiaction between this genetic predisposition
and folate Status on the plasma homocysteme concentration In mdivid
uals with madequate folate Status, the homozygous (+/+) genotype led
to elevated homocysteme levels, contrary to (+/+) individuals with an
adequate folate Status, in whom plasma homocysteme was not elevated
m companson with both other genotypes The fact that 39% of the
cases versus only 17% of the contiols with the (+/+) genotype weie hy-
peihomocystememic, ceitamly imphes the mteraction with and the
existence öl anothei factor determmmg plasma homocysteme levels,
moie often found among cases than controls Whethei this can be
Table 3 Thiombosis nsk due to +/+ genotype m difterent age groups
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Table 4 Relationship between thermolabile MTHFR, factor V Leiden, and the
nsk of deep-vem thiombosis
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* Reference categoiy OR = l, FV Leiden heterozygotes are referred to äs +",
wildtype is referred to äs '-", MTHFR homozygotes (+/+) are referred to äs
"+", heterozygotes (+/-) and wildtype (-/-) are referred to äs "-"
attnbuted to an madequate folate Status in patients could not be
assessed, because the vitamm Status was not determmed m our study
population In a study on hypei homocystemerma m recurrent venous
thrombosis, Den Heijei et al did not find differences m vitamm B12
and folate Status in patients compared with population-based controls
(6, 23) This could also be the case m our study on deep-vem
thiombosis, although a change in dietary mtake of vitamm nutnents due
to a fust episode of thiombosis cannot be ignored
(2) In the LETS-study, äs we leported pieviously (7), the nsk of
venous thrombosis did not mcrease gradually, the odds latios only
mcreased substantially with homocysteme concentrations above
22 μηιοΙ/1, mdicatmg that theie might be a threshold above which
homocysteme has thiombogemc repercussions The MTHFR mutation
itself may not be sufficient to lead to such pronounced homocysteme
elevation, and will only m combmation with an environmental or an-
other genetic facloi lead to such a hyperhomocystememia
(3) The homozygous (+/+) genotype causes a redistnbution of folate
denvatives (12,14) leadmg to a highei availabihty of one-carbon moie-
ties foi thymidme synthesis The lattei may have a concomitant bemfi-
cial effect on the caidiovascular System
(4) Theie could be a, yet undetermmed, stronger determmant of ele-
vated homocysteme levels contubutmg to the nsk of deep vem throm
bosis, a contnbutoi not associated to this genetic defect in MTHFR
This strongei deleimmant may mask a possible effect of the MTHFR
mutation
(5) The obsei vation of an equally distnbution of the 677C-»T trän
sition over both controls and patients even mises the question whether
homocysteme itself is the pnme compound causmg venous thrombosis
and not anothei metabolite related to homocysteme metabohsm but not
associated to theimolabile MTHFR The thrombogemc effect of mildly
elevated homocysteme concentraüons could be dependent of the pn-
mary undeilymg cause of mild hypei homocystemerma Obviously, this
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sheds senous doubts to the Status of mild hyperhomocysteinemia äs an
independent cause of deep-vein thrombosis, and opens the possibility
that hyperhomocysteinemia is only a marker of another defect, which is
the actual cause of an increased risk for deep-vein thrombosis
(23).
Activated protein C resistance (APC-resistance) due to FVL is the
most common inherited cause of venous thrombosis (15) in Europeans
(24). The findings of Mandel et al. (25) in highly consanguineous ho-
mocystinuric families, suggested that concomitant FVL is an absolute
prcrequisite for thrombosis in severe hyperhomocysteinemic patients.
These results challenged the observation of Den Heijer et al. (7), who
observed mildly elevated homocysteine concentrations äs a risk factor
for thrombosis, independent from coexisting abnormalities in hlood
coagulation, such äs protein S-, protein C-, antithrombin deficiency and
APC-resistance. In the Physician's Health Study, an interaction was re-
ported between mild hyperhomocysteinemia and concomitant FVL in
the risk of venous thromboembolism (26).
In the present study, we did not observe an interaction between
thermolabile MTHFR, a major determinant of elevated homocysteine
concentrations, and FVL, indicating that the presence of both genetic
variants do not lead to an additional risk compared with FVL alone.
A number of studies have addressed the MTHFR variant and concomi-
tant FVL in the risk of venous thrombosis, however with contradictory
results (18-20, 27-29). Zhighetti (20) and Gaustadness (27) and their
co-workers observed an overrepresentation of the frequency of joint ab-
normalities in thrombosis patients, indicative of an interaction between
the MTHFR variant and FVL in the risk of venous thrombosis. On the
other hand, several other studies did not report an increased thrombotic
risk in FVL carriers due to thermolabile MTHFR (18, 19, 28, 29). In a
summary estimate, we did not observe an increased risk in jointly af-
fected individuals compared with the risk in individuals with isolated
FVL.
The mechanism by which homocysteine may cause venous throm-
bosis is obscure. Several in vitro studies suggest that homocysteine
interferes with the anticoagulant and fibrinolytic System (30, 31),
although in most studies the homocysteine concentrations applied were
almost ten times higher than those observed in homocystinuria patients.
Furthermore, homocysteine concentrations were added in its free sulf-
hydryl (reduced) form, leading to tremendous shift in redox Status,
whereas in blood almost 99% is present in an oxidated state.
In conclusion, we have demonstrated that the prevalence of the ho-
mozygous 677C-^T mutation in the MTHFR gene is not increased in
patients with deep-vein thrombosis compared to healthy age- and sex-
matched controls, indicating that this mutation itself is not a risk factor
for deep-vein thrombosis. A small risk however, äs previously shown in
coronary artery disease (22), cannot be exluded. A possible interaction
between the 677C^T mutation in the MTHFR gene and FVL was not
observed. Further studies are warranted to elucidate the relationship
between abnormal homocysteine metabolism and its contribution to the
risk of deep-vein thrombosis.
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Vitamin K Deficiency Bleeding (VKDB) in infancy has
a high incidence of intracranial bleeding. Vitamin K
given intramuscuiary at birth is the most effective
way of prophylaxis, but since it was suspected to
increase the risk of childhood cancer it was replaced
in many countries by oral Vitamine K with conse-
quent increase in VKDB. To solve this dilemma inter-
nationally renowned experts presented their contro-
versial standpoints. The facts reported serve äs base
for evaluation of the ideal prophylaxis.
F. K. Schattauer Publishing Co. Stuttgart - New York
Distributors:
United States and Canada:
John Wiley & Sons, Inc., Wiiey-liss Division, 605 Third Avenue, New York, NY 101 58-0012/USA
UK, Eire, Spain, France, The Netherlands and South Africa:
British Medical Journal, BMA House, Travistock Square, London WC1H 9JR
258
